Home › NDC Lookup › RxCUI directory › RxCUI 1739332

Sumatriptan 11 MG Nasal Powder — RxCUI 1739332

RxNorm drug concept · Semantic clinical drug
RxCUI 1739332 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1739332
Official nameSumatriptan 11 MG Nasal Powder
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Sumatriptan: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Sumatriptan stops a migraine that's already started — it does not prevent future attacks. Think of it as a rescue medicine you take when a migraine hits, not something you take eve...
  • What exactly does sumatriptan do — does it prevent migraines or stop them?
  • Take it as soon as you're sure a migraine attack has started. Sumatriptan works by targeting the blood vessels and nerve pathways involved in the attack, so getting it on board ear...
  • When should I take it during a migraine attack?
📖 Read our full Sumatriptan guide →

🕸️ Concept Web — How Sumatriptan 11 MG Nasal Powder Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Sumatriptan 11 MG Nasal Powder RxCUI 1739332

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Sumatriptan 37418
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Onzetra 1739333
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Sumatriptan Nasal Powder 1739331
    • Sumatriptan Nasal Product 1163611
    • Sumatriptan Nasal Powder [Onzetra] 1739335
    • Onzetra Nasal Product 1739336
    • Nasal Powder 1739329
    • Nasal Product 1151130
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Sumatriptan 11 MG SCDC · 1739330
  • Sumatriptan Nasal Powder SCDF · 1739331
  • Sumatriptan Nasal Product SCDG · 1163611

Brand-Name Concepts

  • Sumatriptan 11 MG Nasal Powder [Onzetra] SBD · 1739337
  • Sumatriptan 11 MG [Onzetra] SBDC · 1739334
  • Sumatriptan Nasal Powder [Onzetra] SBDF · 1739335
  • Onzetra Nasal Product SBDG · 1739336
  • Onzetra BN · 1739333

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1739332 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
42847-0311-08 8 POUCH in 1 CARTON (42847-311-08) / 2 CAPSULE in 1 POUCH Onzetra Xsail Currax Pharmaceuticals LLC 2015-10-01
Observed labelers: Currax Pharmaceuticals LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.